Date Time
Coronavirus: Weak Point of Remdesivir
The drug Remdesivir only weakly inhibits the new coronavirus SARS-CoV-2. Research groups from Göttingen and Würzburg have discovered why this is so.
The Covid-19 drug Remdesivir (purple) is incorporated into the new RNA chain during the copying process and suppresses the duplication of the coronavirus genome. (Image: Hauke Hillen, Goran Kokic, Patrick Cramer / Max-Planck-Institut für biophysikalische Chemie Göttingen)
Remdesivir is the first drug against Covid-19 to be conditionally approved in Europe and the United States. The drug is designed to suppress the rapid replication of the SARS-CoV-2 virus in human cells by blocking the viral copying machine, called RNA polymerase.